Chimeron Bio welcomes Tony de Fougerolles to its Board of Directors

– USA, PA –  Chimeron Bio, an RNA company developing self-amplifying RNA vaccines and therapeutics, today announced the appointment of Tony de Fougerolles to its Board of Directors.

“I can’t adequately express our excitement to welcome Tony to the Chimeron Bio board. He is widely considered a visionary in the field of RNA technology, having played a key role in developing and advancing mRNA and RNAi platforms from inception and into the clinic. In addition to his scientific expertise, he has been instrumental in scaling multiple, multi-billion-dollar companies,” said Board Chairman, Dr. Afshin Safavi.

About Antonin de Fougerolles

As the former founding CSO of Moderna, Tony is a pioneer in RNA technology with a long track record of successfully scaling biotechnology organizations from the start-up stage.

“The saRNA technology Chimeron has developed using its proprietary ChaESAR™ platform is orders of magnitude improved over linear mRNA and other saRNA approaches and represents the next generation of RNA vaccines and therapeutics. The pipeline of drugs Chimeron is developing is exciting and can have a truly transformational impact for patients across a wide variety of diseases,” said Tony de Fougerolles

About Chimeron Bio

Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA towards the development of novel RNA drugs and vaccines for various diseases. The company uses its proprietary ChaESAR platform to develop a pipeline in oncology, rare genetic disorders, and infectious diseases. It is developing two COVID-19 vaccine candidates each with its unique mechanism of action. The candidates have shown strong promise in early safety assessment and are under further development.

Chimeron Bio is actively developing next-generation saRNA-based medicines for Oncology, Infectious Diseases, and Rare Diseases.

For more information: https://www.chimeron.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.